NCT01866306View on ClinicalTrials.gov

A Study to Evaluate the Safety and Use of Human Rhinovirus in Healthy and Asthmatic Participants (MK-0000-218)

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

October 22, 2013

Primary Completion Date

December 25, 2015

Study Completion Date

January 18, 2016

Conditions
Asthma
Interventions
BIOLOGICAL

RV16UB

RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.

DRUG

LABA

Asthmatic participants were treated with LABA as part of their standard of care

All Listed Sponsors
collaborator

U-BIOPRED Consortium

UNKNOWN

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01866306 - A Study to Evaluate the Safety and Use of Human Rhinovirus in Healthy and Asthmatic Participants (MK-0000-218) | Biotech Hunter | Biotech Hunter